drugset / Trial / NCT05987033

Proof-of-concept Study With NVDX3 for Treatment of Distal Radius Fractures.

NCT05987033 ↗

Phase 1/2 Completed 11 enrolled Novadip Biosciences
NaSingle-groupOpen-labelTreatment

Summary

Prospective, single arm, monocentric clinical study to test NVDX3 in patients suffering from distal radius fracture. NVDX3 will be implanted during a single surgical intervention.

Timeline

Start
2023-08-08
Primary completion
2024-12-19
Completion
2024-12-19

Drugs

EvaluationDrugModalityDoseRoute
Subject NVDX3 Other / unclassified — Other

Indications

No indication recorded.